Key facts
- This page summarizes Jeffrey Busch's Form 4 filing for Global Medical REIT Inc. (GMRE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2025, 20:49.
Jeffrey Busch - 26 Feb 2025 Form 4 Insider Report for Global Medical REIT Inc. (GMRE)
- Reporting relationship
- Chairman, President and CEO, Director
- Issuer ticker
- GMRE
- Reported as of
- 26 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2025, 20:49:42 UTC
- Prior SEC filing
- 02 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jamie Barber, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Busch filed Form 4 for Global Medical REIT Inc. (GMRE) on 27 Feb 2025.
Change
- Previous filing in this sequence was filed on 02 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GMRE
transaction
Derivative
LTIP Unit (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +23,613
- Change %
- +3.3%
- Price
- $0.000000
- Shares after
- 745,015
- Date
- 26 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,613
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 26, 2025, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2024 and February 26, 2025 and 50% of the LTIP Units will vest on February 26, 2026 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date.
Footnote F2
As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.